ADHD telehealth in the UK has been one of the most scrutinised clinical categories since 2023, when BBC Panorama raised public questions over private diagnostic standards. The clinical pathway is real and valuable; the regulatory frame has tightened. This piece walks through what good private ADHD telehealth looks like in 2026 — diagnostics, prescribing, shared-care, and CD-register procedures.
The current UK ADHD diagnostic and treatment pathway
NICE NG87 sets out diagnostic and treatment guidance for ADHD in the UK. Diagnosis requires comprehensive clinical assessment by an appropriately qualified clinician. Treatment options include behavioural therapy and pharmacological treatment. Stimulant medications including methylphenidate and lisdexamfetamine are Schedule 2 controlled drugs.
Right-to-choose and how private telehealth fits into NHS pathways
NHS Right-to-Choose allows patients in England to request specialist referrals to private providers under qualified-provider arrangements. This has driven significant private-sector activity in ADHD assessment. The pathway is real but administratively burdensome and requires the patient's GP to be engaged in the broader care plan.
Shared-care agreements — what they are, when GPs accept them, why they often decline
Shared-care agreements transfer ongoing prescribing responsibility from a private specialist to an NHS GP after treatment is initiated. GPs can decline shared-care arrangements for various reasons including capacity, indemnity, or clinical disagreement. NHS England issued shared-care guidance updates in 2024 in response to capacity concerns.
Schedule 2 stimulant prescribing under remote care
Methylphenidate and lisdexamfetamine are Schedule 2 controlled drugs. Remote prescribing of Schedule 2 medications is permitted but the clinical bar is high. The prescriber must be appropriately qualified, the assessment must be defensible, and the dispensing must follow full CD-register procedures under the Misuse of Drugs Regulations 2001.
Patient safeguarding and titration — what good practice looks like
Good practice in ADHD telehealth includes: structured initial assessment with documented rating scales, careful dose titration with regular review, monitoring of cardiovascular parameters, mental-health screening, substance-use screening, and clear handoff documentation if shared-care is achieved. Patient safeguarding is the foundation, not the polish.
What changed in 2024 to 2026 around ADHD telehealth scrutiny
BBC Panorama in 2023 raised public scrutiny over private ADHD diagnostic standards. CQC has paid close attention to digital ADHD providers since. NHS England's 2024 shared-care guidance update reflected capacity pressures. The net effect is a higher bar for private operators — which has improved the credible category but constrained operators who treated it as a growth play.
The clinical bar for remote ADHD prescribing rose materially after 2023. Operators who treat ADHD telehealth as a high-volume conversion play face higher regulatory risk than they did three years ago.
Patient safeguarding is the foundation, not the polish.
ADHD telehealth done well is genuinely valuable — it makes a real treatment accessible to patients who otherwise wait years for NHS assessment. Done badly, it has become the case study for what regulators want to stop. The line between those two operating models is now clearly drawn.
